Johnson Dunn Capital Advisors Inc’s Grace Therapeutics GRCE Stock Holding History

Johnson Dunn Capital Advisors Inc’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$41.9K	Buy	+19,500	New	+$43.3K	0.03%	153

Other funds holding GRCE

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

AXQ Capital Jersey City, New Jersey $764M AUM 4.44% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Arax Advisory Partners Denver, Colorado $17.7B AUM 20.22% 1-Year Est. Return

Johnson Dunn Capital Advisors Inc's GRCE Position: Q3 2026 in Review

Johnson Dunn Capital Advisors Inc opened a new position in Grace Therapeutics (GRCE) in Q3 2026: 19,500 shares worth $41.9K. The stake represents 0.03% of the portfolio and ranks #153 among its holdings.

18 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.

Johnson Dunn Capital Advisors Inc held 19,500 shares of Grace Therapeutics worth $41.9K as of Q3 2026.
Grace Therapeutics was a new Johnson Dunn Capital Advisors Inc position in Q3 2026.
Grace Therapeutics made up 0.03% of Johnson Dunn Capital Advisors Inc's portfolio in Q3 2026, its #153 holding.
18 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.

Based on Johnson Dunn Capital Advisors Inc's 13F filing for Q3 2026, filed 12 Nov 2026.